Zacks.com on MSN7h
Here's Why You Should Retain DexCom Stock in Your Portfolio for NowThe expansion in the underpenetrated Type 2 diabetes market should support DXCM’s top-line growth going forward. In June, ...
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors ...
Everyday Health on MSN9mon
FDA Approves the First Over-the-Counter Continuous Glucose Monitor (CGM)Dexcom, the maker of the G6 and G7 continuous glucose monitor (CGM ... online doctor consultations with CGM sales and ongoing ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback